NEW YORK (GenomeWeb News) - German-based TheraCode, a wholly owned subsidiary of biotech firm BioNTech, has announced its intentions to buy JPT Peptide Technologies, also based in Germany, for €5 million ($6.8 million) in an all-cash deal.

JPT had been a wholly owned subsidiary of Jerini, which sold the company as part of its strategy to divest non-strategic businesses and focus on its core business, the commercialization of the drug icatibant (Firazyr) for the treatment of hereditary angioedema.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.